Are these 2 legal eagles set to pounce?

These 2 legal companies have differing income growth profiles; however both remain significantly undervalued.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One dependable activity in a changing world is the chronic repetition of commercial bad behaviour and this is the area where litigation funder Bentham IMF (ASX: IMF) finds investment opportunities.

Over 13 years of operation Bentham IMF's record is outstanding with 73% of cases won or settled, 23% withdrawn and only 4% lost. At present, the case portfolio (cases underway or documents of claim to be lodged) stands close to $2billion, providing a pipeline of yet to be concluded cases over the next few years.

As a rough guide, the net potential profit to be realised from the current portfolio is between $160m – $200m, with a median case completion of 2.25 years. Potential investors should note this is not a company with a year-on-year predictable earnings stream as the legal process takes its own time.

Bentham IMF currently has offices in Australia and the US (New York and Los Angeles). It is also contemplating London as a European base. Growth opportunities include further development of US and European operations.

Bentham IMF is a highly astute and well structured litigation funder with the best performance record in the business. Indicative earnings per share estimates (adjusted for recently completed issues) are 18c in 2014 and 30c in 2015. The dividend payout should be approximately 50% of earnings. However these figures are indicative only – legal proceedings can be protracted. At present Bentham IMF has no borrowings and a strong net cash position.

Bentham IMF is one of my favourite companies and happily occupies a significant percentage of my portfolio.

If you're contemplating an investment in the legal business, Slater & Gordon (ASX: SGH) has a more predictable earnings stream and also strong growth prospects. Well known to Australians, Slater & Gordon has moved aggressively into the UK market (five times Australia's size and much more crusty) with considered purchases of compatible legal practices.

Slater & Gordon's major areas of expertise include employment law, industrial law, medical negligence and personal injury – broadly known as the consumer law segment. Slater & Gordon dominates this segment in Australia and is estimated to have 5% of the UK market, rapidly gaining on market-leader Irwin Mitchell which has 7%.

The UK market is highly fragmented and other acquirers have entered over the past 12 months, although Slater & Gordon retains first mover advantage. Following the recent acquisition of Pannone Solicitors, Slater & Gordon is now likely to consolidate and put further resources into building the brand in the UK.

Allowing for recent acquisitions, net debt/equity stands at 29%. Finance facilities have been renewed and Slater & Gordon has an internal gearing ratio target of 30%-45%. I wouldn't like to see the upper level being tested unless further acquisitions offer extremely compelling value.

Earnings per share are forecast to be 26c in 2014, 32c in 2015 and 34c in 2016 – placing Slater & Gordon on a price to earnings ratio of 17.7, 14.4 and 13.5 respectively. Dividends are likely to be minimal (between 2%-3% of net profit).

One of the best market performers over 2013, Slater & Gordon has further to run.

Foolish takeaway

Although acquiring and integrating white collar service businesses can be tricky (just think of some of the disasters the accounting profession has brought to the ASX), the well managed Slater & Gordon has to date been highly successful in this regard. The momentum achieved in the UK looks like continuing and Slater & Gordon still appeals as a relatively conservative long-term small-cap investment with a growing earnings stream.

Classified as a diversified financial, Bentham IMF is gaining operational traction in the US and Europe, adding to a considerable Australian legal case portfolio. Bentham IMF strongly appeals as a high-quality small-cap investment with significant medium and long-term upside. However it is not suitable for those after a predictable annual income.

Shine Corporate (ASX: SHJ) is another listed legal services company – yet to be investment grade, in my view.

Motley Fool contributor Peter Andersen owns shares in Bentham IMF and Slater & Gordon

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »